5 февр. 2024 г. · Catalent and Novo Holdings have entered into a merger agreement in an all-cash transaction that values Catalent at $16.5 billion.

22 нояб. 2024 г. · Novo Holdings is set to gain unconditional EU antitrust approval for its planned $16.5 billion takeover of U.S. contract drug maker Catalent ...

3 нояб. 2024 г. · Novo Holdings will acquire, in an all-cash deal, all outstanding shares of Catalent for $63.50 per share. This purchase price represents a 16.5% ...

30 окт. 2024 г. · Currently, Novo Holdings' proposed deal is under review by the FTC, which asked for additional information related to the acquisition in May.

23 окт. 2024 г. · Under the current plan, Novo Nordisk is in line to purchase three Catalent fill-finish facilities from Novo Holdings for $11 billion after the ...

Catalent has entered into an agreement to be acquired by Novo Holdings, a global investment firm focused on life sciences.

24 окт. 2024 г. · In February 2024, Novo Holdings announced the $16.5 billion acquisition of Catalent, a deal that would ultimately see Novo Nordisk taking ...

21 окт. 2024 г. · Catalent's acquisition by Novo Holdings is expected to close towards the end of calendar year 2024, subject to customary closing conditions.

5 нояб. 2024 г. · Catalent said the deal is expected to close towards the end of this year, after which the parent firm will sell three of the contract ...

22 окт. 2024 г. · Novo Holdings' proposed acquisition of drugmaker Catalent was approved without restrictions by the Brazilian competition authority, ...